drugset / Trial / NCT01725113
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
RandomizedCrossoverSingle-blindTreatment
Summary
The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO) parathyroid hormone targets.
Timeline
- Start
- 2012-11
- Primary completion
- 2013-12
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcitriol | Small molecule | — | Intravenous |
| Subject | Paricalcitol | Other / unclassified | — | — |